149 related articles for article (PubMed ID: 36129915)
21. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
23. Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Aydemirli MD; van Eendenburg JDH; van Wezel T; Oosting J; Corver WE; Kapiteijn E; Morreau H
Endocr Relat Cancer; 2021 May; 28(6):377-389. PubMed ID: 33878728
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer.
Kwak B; Kim DU; Kim TO; Kim HS; Kim SW
Int J Oncol; 2018 Oct; 53(4):1800-1808. PubMed ID: 30066856
[TBL] [Abstract][Full Text] [Related]
25. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
26. USP44 suppresses proliferation and enhances apoptosis in colorectal cancer cells by inactivating the Wnt/β-catenin pathway via Axin1 deubiquitination.
Huang T; Zhang Q; Ren W; Yan B; Yi L; Tang T; Lin H; Zhang Y
Cell Biol Int; 2020 Aug; 44(8):1651-1659. PubMed ID: 32285989
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements.
Malki A; ElRuz RA; Gupta I; Allouch A; Vranic S; Al Moustafa AE
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374459
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer.
Gan T; Stevens AT; Xiong X; Wen YA; Farmer TN; Li AT; Stevens PD; Golshani S; Weiss HL; Evers BM; Gao T
Oncogene; 2020 Oct; 39(44):6789-6801. PubMed ID: 32973331
[TBL] [Abstract][Full Text] [Related]
29. PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
Novellino L; De Filippo A; Deho P; Perrone F; Pilotti S; Parmiani G; Castelli C
Cell Signal; 2008 May; 20(5):872-83. PubMed ID: 18276111
[TBL] [Abstract][Full Text] [Related]
30. Genomic and transcriptomic analysis of Korean colorectal cancer patients.
Jeon SA; Ha YJ; Kim JH; Kim JH; Kim SK; Kim YS; Kim SY; Kim JC
Genes Genomics; 2022 Aug; 44(8):967-979. PubMed ID: 35751785
[TBL] [Abstract][Full Text] [Related]
31. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
32. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
33. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
34. LUCAT1 promotes colorectal cancer tumorigenesis by targeting the ribosomal protein L40-MDM2-p53 pathway through binding with UBA52.
Zhou Q; Hou Z; Zuo S; Zhou X; Feng Y; Sun Y; Yuan X
Cancer Sci; 2019 Apr; 110(4):1194-1207. PubMed ID: 30690837
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
36. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.
Siemens H; Jackstadt R; Kaller M; Hermeking H
Oncotarget; 2013 Sep; 4(9):1399-415. PubMed ID: 24009080
[TBL] [Abstract][Full Text] [Related]
37. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
39. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
40. Integrated Network Pharmacology Analysis and
Yang H; Cheung MK; Yue GG; Leung PC; Wong CK; Lau CB
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
